SPONSOR
Children's Oncology Group
Total Trials
6
Recruiting
6
Phases
Phase 1, Phase 2, Phase 3, Phase 1, Phase 2
Conditions studied: Diffuse Midline Glioma, H3 K27-AlteredMetastatic Malignant Neoplasm in the Central Nervous SystemRecurrent Diffuse Intrinsic Pontine GliomaRecurrent Diffuse Midline Glioma, H3 K27-AlteredRecurrent LymphomaRecurrent Malignant Solid NeoplasmRecurrent Primary Malignant Central Nervous System NeoplasmRefractory LymphomaRefractory Malignant Solid NeoplasmRefractory Primary Malignant Central Nervous System Neoplasm
Children's Oncology Group is a clinical research sponsor with 6 registered studies on ClinicalTrials.gov, of which 6 are actively recruiting participants. Research covers conditions including Diffuse Midline Glioma, H3 K27-Altered, Metastatic Malignant Neoplasm in the Central Nervous System, Recurrent Diffuse Intrinsic Pontine Glioma, Recurrent Diffuse Midline Glioma, H3 K27-Altered.
The trial portfolio spans Phase 1, Phase 2, Phase 3, Phase 1 studies, reflecting a pipeline that may include early-stage safety evaluations, mid-stage efficacy assessments, and large-scale confirmatory trials. All studies listed here are sourced directly from ClinicalTrials.gov and updated daily.
Frequently Asked Questions — Children's Oncology Group
How many clinical trials has Children's Oncology Group sponsored?
ClinicalMetric currently tracks 6 clinical trials sponsored by Children's Oncology Group, of which 6 are actively recruiting participants. These trials cover conditions including Diffuse Midline Glioma, H3 K27-Altered, Metastatic Malignant Neoplasm in the Central Nervous System, Recurrent Diffuse Intrinsic Pontine Glioma. Trial counts are updated daily from ClinicalTrials.gov and reflect currently registered studies.
What therapeutic areas does Children's Oncology Group research focus on?
Children's Oncology Group clinical trials span Diffuse Midline Glioma, H3 K27-Altered, Metastatic Malignant Neoplasm in the Central Nervous System, Recurrent Diffuse Intrinsic Pontine Glioma, Recurrent Diffuse Midline Glioma, H3 K27-Altered, Recurrent Lymphoma, and additional conditions. The research pipeline includes Phase 1, Phase 2, Phase 3, Phase 1 trials, reflecting work from early-stage safety evaluation through large-scale efficacy studies.
How do I participate in a Children's Oncology Group clinical trial?
To participate in a Children's Oncology Group trial, review the active studies listed on this page, check each trial's specific eligibility criteria on ClinicalTrials.gov, and contact the trial site directly—not the sponsor's headquarters. Trial sites are academic medical centers, hospitals, or specialized research clinics. Your physician can facilitate a referral. ClinicalMetric lists all Children's Oncology Group trials with current recruitment status updated daily.
Clinical Trials by Children's Oncology Group
NCT04870944 Phase 1, Phase 2
Recruiting
CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma
Diffuse Midline Glioma, H3 K27-Altered
NCT06620302 Phase 1, Phase 2
Recruiting
Testing the Addition of an Anti-cancer Drug, DT2216, to the Usual Chemotherapy Treatment for Relapsed or Refractory Solid Tumors and Fibrolamellar Carcinoma
Childhood Fibrolamellar Carcinoma
NCT04851119 Phase 1, Phase 2
Recruiting
Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
Colorectal Carcinoma
NCT06647953 Phase 3
Recruiting
Testing a Standardized Approach to Surgery and Chemotherapy for Type I Pleuropulmonary Blastoma or the Addition of an Anti-cancer Drug, Topotecan, to the Usual Treatment for Types II and III Pleuropulmonary Blastoma
Pleuropulmonary Blastoma
NCT06894979 Phase 1
Recruiting
Testing the Addition of an Anti-Cancer Drug, AZD1390, During Radiation Therapy for Newly Diagnosed High Grade Glioma, Diffuse Midline Glioma, or Diffuse Intrinsic Pontine Glioma
Childhood Astrocytoma
NCT04322318 Phase 2
Recruiting
A Study of Combination Chemotherapy for Patients With Newly Diagnosed DAWT and Relapsed FHWT
Anaplastic Kidney Wilms Tumor
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: July 2026 · Data Methodology